First slide
Sureseq Logo

Product summary

  • Technology NGS
  • Application Haematology
  • Areas of interest Myeloid
  • Panel Size 42 Kb
  • Gene Targets 25
  • Aberration Types SNV, indel
  • Product No. 600075 (16 reactions)
    600076 (96 reactions)
  • Intended use For research use only; not for diagnostic procedures.

Overview

Introduction

A 25-gene myeloid disorders hybridisation-based NGS enrichment panel with complimentary Interpret NGS data analysis software that delivers accurate and easy identification of variants. The panel includes key genes implicated in MPNs and MDS such as JAK2, CALR, MPL and KIT.

Features
  • Designed in collaboration with recognised cancer experts - Detect SNVs and indels in 25 genes implicated in a variety of MPNs
  • Time and cost saving solution - Replace multiple single gene assays with one comprehensive panel
  • Fast and easy workflow - Streamlined library preparation, rapid hybridisation and intuitive software allowing easy variant analysis
  • Unparalleled uniformity and high depth of coverage - Detect low-frequency variants down to 1% VAF with confidence

Gene targets

Select a gene to view exon coverage examples:

* Exon examples not yet available

Capabilities

Designed in collaboration with recognised cancer experts

Myeloproliferative neoplasms (MPNs) are a group of diseases that affect normal blood cell production in the bone marrow resulting in overproduction of one or more cell types (i.e. red cells, white cells or platelets). There are numerous different sub-types of MPNs that are distinguished from each other by the type of cell which is most affected and the genetic profile. The SureSeq™ Myeloid Panel targets selected key genes known to contain driver mutations for a range of MPNs including polycythaemia vera (PV), essential thrombocythaemia (ET) and myelofibrosis (MF). The gene content has been defined with input from recognised cancer experts including Professor Mike Griffiths (West Midlands Regional Genetics Laboratory, UK) and Professor Nick Cross (National Genetics Reference Laboratory – Wessex, UK) (Table 1). To obtain the optimal sensitivity whilst maximising throughput, we have targeted hot exons where clinically relevant mutations are known and every exon for tumour suppressor, hereditary and highly implicated research-related genes. This allows for detection of previously characterised as well as novel variants in myeloid samples.

Time and cost saving solution

Genetic analysis of single nucleotide variants (SNVs) and indels in myeloid-implicated genes is a reliable way of distinguishing between different subtypes of MPNs. Instead of assaying for single genes in a sequential manner, the mutational status of 25 genes can be rapidly and simultaneously determined with the use of the SureSeq Myeloid Panel. This approach therefore offers both a time and cost-effective solution.

Sensitive and reproducible variant detection even in heterogeneous samples

Heterogeneous cancer samples pose significant challenges as alleles are likely to be present at a lower fraction than what would be expected for standard germline variants. Samples typically contain a mixture of cancer and normal cells; moreover, cancer can consist of several molecularly distinct clones. In order to detect alleles that contribute only a small percentage to the reads at any locus, a highly uniform and sensitive enrichment is required. The SureSeq Myeloid Panel has been validated with samples from the National Institute for Biological Standards and Control (NIBSC) and has been shown to accurately detect alleles down to 1% variant allele fraction (VAF) at a read depth of >1000x (Table 2).

A typical laboratory workflow might be to pool and run 24 samples in a single Illumina MiSeq lane. The SureSeq Myeloid Panel can reliably and routinely detect somatic mutations down to 1% VAF under these conditions at the following sites of interest in MPNs:

  • JAK2 (exon 12 – AAs 536-547)
  • JAK2 (V617F)
  • MPL (W515)
  • CALR (exon 9 indels)
  • KIT (D816V)
  • TET2 (R550)

Analysis in clinical research samples has shown that the panel is able to reliably detect not only SNVs but also deletions of up to 52 bp, which are particularly informative in the CALR gene (Table 3).

Fast and easy workflow

Hybridisation-based enrichment is now well recognised as providing superior results over amplicon-based enrichment technology. To date, the protocol has required more DNA and the library preparation procedure has been longer and more complex. In combination with the OGT SureSeq Library Preparation Kit, these issues have been addressed. There are fewer hands-on steps, turnaround times have been significantly improved, and the panel has been optimised to work with as little as 500 ng of genomic DNA derived from whole blood.

Interpret — OGT’s powerful, standalone NGS data analysis package — is provided free with the SureSeq Myeloid Panel and allows the conversion of FASTQ files into an intuitive interactive report. The user-friendly report makes it easy to set up complex filtering rules with multiple parameters.

Variants are fully annotated with links to various databases (e.g. dbSNP, COSMIC, Genecards and OMIM) providing results in context. Each variant can be reviewed in the Integrative Genomics Viewer (IGV) from the Broad Institute (Figure 2).

Excellent coverage uniformity

Enrichment assay optimisation is a crucial step in ensuring accuracy and sensitivity of targeted sequencing. Where regions are poorly enriched, they will generate fewer sequencing reads. If a variant falls into a region that is not covered at all, or covered by only a few reads, that variant is likely to be missed. OGT’s expert bait design ensures efficient and more uniform capture of all targeted regions, so that all variants present can be called with maximum confidence. This has been demonstrated on the CALR gene, which is commonly mutated in various MPNs. It is critical to identify key CALR indels (types 1 & 2 causing a frameshift) as well as increasingly recognised point mutations in this gene. The SureSeq Myeloid Panel delivers superior performance to panels designed using standard algorithms by ensuring uniform coverage over the regions of interest (Figure 3).

SureSeq Myeloid Panel workflow

Content selection Image

Content selection

Border Image
  • SureSeq Myeloid Panel
Sequencing Image

Sequencing

Border Image
  • Illumina sequencers

What our customers say

Request a quote for this product

View all products

NGS resources & support